<DOC>
	<DOC>NCT01413906</DOC>
	<brief_summary>The purpose of this study is to evaluate the tolerability and safety profile of BMS-833923 (XL139) when orally administered on a once daily schedule.</brief_summary>
	<brief_title>Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Subjects with advanced or metastatic solid tumors refractory to, or relapsed from, standard therapies or for which there is no known effective treatment Men and woman, 20 years of age and above Subjects with symptomatic brain metastasis or active brain metastasis requiring treatments Inability to swallow oral medication Uncontrolled or significant cardiovascular disease Inadequate bone marrow function Inadequate hepatic function Inadequate renal function Pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>